Emma Andrus, Editor

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Researchers reported the case of a 28-year-old woman with epidermodysplasia verruciformis who developed SCC on a sun-protected scalp.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of April.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Learn more about the in-depth topics covered in the March 2025 print issue of Dermatology Times.

Dermatology Times is looking back on the top stories in dermatology from the month of March.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Xyngari showed promise as the first once-weekly topical acne treatment, achieving strong phase 3 results with significant efficacy and safety.

Dermatology Times is recapping our exclusive expert interviews from the month of March.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

A study shows active educational interventions improve melanoma detection rates and rule application, with lasting effects over time.

This review of the latest dermatologic studies includes insights into atopic dermatitis, including results from a novel topical CBD application, skin mycobiome comparison, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Nanoneedles boosted CRISPR base editing efficiency in RDEB fibroblasts, enabling precise COL7A1 correction and improved cell function.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

At the 2025 AAD Annual Meeting, Alumis Inc. presented promising phase 2 STRIDE trial results for ESK-001, a TYK2 inhibitor showing sustained psoriasis improvements over 52 weeks.

The lowest-dose oral minocycline for rosacea is now available by prescription following FDA approval in November 2024.